AstraZeneca Looks To FluMist Experience In COVID-19 Efforts
The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.
You may also be interested in...
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.